Table 1 PROTACs currently in clinical trials
From: Cellular parameters shaping pathways of targeted protein degradation
Name | Company | Target | E3 ligase | Indication | Phase |
|---|---|---|---|---|---|
ARV-110 | Arvinas | AR | CRBN | mCRPC | II NCT03888612 |
ARV-393 | Arvinas | BCL6 | CRBN | R/R NHL, R/R AITL | I NCT06393738 |
ARV-471 | Arvinas | ER | CRBN | ER + /HER2- breast cancer | III NCT05654623 |
ARV-766 | Arvinas | AR | CRBN | mCRPC | II NCT05067140 |
ASP3082 | Astellas Pharma | KRASG12D | UD | Solid Tumour | I NCT05382559 |
BGB-16673 | BeiGENE | BTK | CRBN | B-cell malignancies | II NCT05294731 |
CC-94676 | BMS | AR | UD | mCRPC | I NCT04428788 |
CFT-8634 | C4 Therapeutics | BRD9 | CRBN | Synovial sarcoma, SMARCB1-null solid tumours | II NCT05355753 |
CFT-1946 | C4 Therapeutics | BRAF | CRBN | BRAFV600E-driven cancers | II NCT05668585 |
CG001419 | Cullgen | NTRK | CRBN | Solid tumours | II CTR20222742 |
DT-2216 | Dialectic Therapeutics | BCL-XL | VHL | T-cell lymphomas | I NCT04886622 |
GT-20029 | Kintor Pharmaceutical | AR | CRBN | Acne vulgaris | I NCT05428449 |
HP518 | Hinova | AR | UD | mCRPC | I NCT06155084 |
HSK-29116 | Haisco | BTK | CRBN | B-cell malignancies | I NCT04861779 |
KT-253 | Kymera Therapeutics | MDM2 | UD | R/R high grade myeloid malignancies and solid tumours | I NCT05775406 |
KT-333 | Kymera Therapeutics | STAT3 | VHL | Liquid and solid tumours, T cell lymphomas | I NCT05225584 |
KT-474 | Kymera Therapeutics | IRAK4 | CRBN | Hidradenitis suppurativa | II NCT06028230 |
NX-2127 | Nurix Therapeutics | BTK, IKZF1, IKZF3 | CRBN | R/R B cell malignancies | Ia/Ib NCT04830137 |
NX-5948 | Nurix Therapeutics | BTK | CRBN | R/R B cell malignancies | Ia/Ib NCT05131022 |
PRT3789 | Prelude Therapeutics | SMARCA2 | UD | NSCLC | I NCT05639751 |
RO7656594 | Roche | AR | UD | Advanced or metastatic prostate cancer | I NCT05800665 |
